Abstract
IT is well recognized that monoamine oxidase (monoamine: O2 oxidoreductase (deaminating), EC 1.4.3.4) (MAO) plays an important role in the degradation of biologically active monoamines in the brain1,2. There is much evidence pointing to changes in monoamine metabolism in mental illnesses characterized by alterations in mood3,4. Perhaps the most important property of MAO inhibiting drugs is their ability to bring about a lightening of affect in depressed patients5. That this effect results solely from the inhibition of MAO has not been widely questioned, although the antidepressive effect is not shared to an equal extent by all drugs in the group6. An attempt has been made to explain this finding in terms of differing ability of the MAO inhibitors to prevent amine re-uptake7; however, it has seemed to us that an explanation might better be sought in terms of differential inhibitory capacity of these drugs on the four molecular variants of MAO in the human brain8.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kopin, I. J., Pharmacol. Rev., 18, 513 (1966).
Roffler-Tarlov, S., Sharman, D. F., and Tegerdine, D., Brit. J. Pharmacol., 42, 343 (1971).
Schildkraut, J. J., in Biochemistry, Schizophrenia and Affective Illnesses (edit. by Himwich, H. E.), 198 (Williams and Wilkins, Baltimore, 1970).
Himwich, H. E., in Biochemistry, Schizophrenia and Affective Illnesses (edit. by Himwich, H. E.), 230 (Williams and Wilkins, Baltimore, 1970).
Hordern, A., New Engl. J. Med., 272, 1159 (1965).
Davis, J. M., Arch. Gen. Psychiat., 13, 552 (1965).
Hendley, E. D., and Snyder, S. H., Nature, 220, 1330 (1968).
Youdim, M. B. H., Collins, G. G. S., and Sandler, M., Nature, 223, 626 (1969).
Collins, G. G. S., Sandler, M., Williams, E. D., and Youdim, M. B. H., Nature, 225, 817 (1970).
Sandler, M., Collins, G. G. S., and Youdim, M. B. H., in Mechanisms of Toxicity (edit. by Aldridge, W. N.), 4 (Macmillan, London, 1971).
Hawkins, J., Biochem. J., 50, 577 (1952).
Kraml, M., Biochem. Pharmacol., 14, 1684 (1965).
Robinson, D. S., Lovenberg, W., Keiser, H., and Sjoerdsma, A., Biochem. Pharmacol., 17, 109 (1968).
Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J., J. Biol. Chem., 193, 265 (1951).
Youdim, M. B. H., and Sourkes, T. L., Canad. J. Biochem., 44, 1397 (1966).
Youdim, M. B. H., Collins, G. G. S., and Sandler, M., in Enzymes and Isoenzymes. Structure, Properties and Function, Fifth FEBS Meeting (edit. by Shugar, D.), 18, 281 (Academic Press, London, 1970).
Pletscher, A., Gey, K. F., and Burkard, W. P., in Handbook of Experimental Pharmacology, 5-Hydroxytryptamine and Related Indolalkylamines (edit. by Erspamer, V.), 19, 593 (Springer, Berlin, 1966).
Johnson, J. P., Biochem. Pharmacol., 17, 1285 (1968).
Lader, M. H., Sakalis, G., and Tansella, M., Psychopharmacologia, 18, 118 (1970).
Asatoor, A. M., Levi, A. J., and Milne, M. D., Lancet, ii, 733 (1963).
Blackwell, B., Lancet, ii, 414 (1963).
Blackwell, B., Lancet, ii, 849 (1963).
Youdim, M. B. H., in Monoamine Oxidases. New Vistas (edit. by Costa, E., and Sandler, M.) (Raven Press, New York, in the press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
YOUDIM, M., COLLINS, G., SANDLER, M. et al. Biological Sciences: Human Brain Monoamine Oxidase: Multiple Forms and Selective Inhibitors. Nature 236, 225–228 (1972). https://doi.org/10.1038/236225b0
Received:
Issue Date:
DOI: https://doi.org/10.1038/236225b0
This article is cited by
-
IN SILICO and IN VITRO Estimation of MAO-B Inhibitory Activity of Newly Synthesized Hydrazones Bearing a Pyrrole Heterocyclic System
Pharmaceutical Chemistry Journal (2023)
-
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases
Journal of Neural Transmission (2018)
-
Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor
Journal of Neural Transmission (2013)
-
Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5‐HT in the UK
British Journal of Pharmacology (2008)
-
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
British Journal of Pharmacology (2006)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.